ST Innovative Diagnostics
Monitoring Malignancies trough a Simple Blood Test
Company Overview
Snapshot
Founded in July 2022 by Esther Rabizadeh, ST Innovative Diagnostics operates with 1–10 employees. The company has secured $70,000 in total capital across one funding round.
Business overview
ST Innovative Diagnostics develops a novel blood-based malignancy monitoring test, leveraging research from Rabin Medical Center and Tel Aviv University. Its proprietary technology measures Fibrinogen Like Protein 2 (FGL2) activity in platelets, enabling non-invasive disease monitoring and relapse prediction across various malignancies. The company serves the Health Tech & Life Sciences sector, with applications in cancer diagnostics, medical devices, and early detection, and plans to expand into solid tumor monitoring and diagnosis.
Strategic signal
A May 2024 publication in journals.plos.org highlighted the presence and activity of Fibrinogen like protein 2 in platelets. This research underpins ST Innovative Diagnostics' core technology, validating the scientific basis for its blood-based malignancy monitoring test and signaling potential for further advancements in non-invasive cancer diagnostics.
Log in to access full profile ›Company Intelligence Q&A
- What is ST Innovative Diagnostics' core technology?
- ST Innovative Diagnostics has developed a proprietary technology and kit that measures Fibrinogen Like Protein 2 (FGL2) activity in platelets, enabling non-invasive disease monitoring and relapse prediction across multiple malignancies.
- When was ST Innovative Diagnostics founded?
- ST Innovative Diagnostics was founded in July 2022.
- Which markets does ST Innovative Diagnostics target?
- ST Innovative Diagnostics targets the global market with a focus on cancer diagnostics, medical devices, and early detection within the Health Tech & Life Sciences sector.
- What is the status of ST Innovative Diagnostics' product development?
- ST Innovative Diagnostics' product, LymFollow, is currently in the clinical trial stage. Proof-of-concept clinical studies have shown high correlation with PET/CT imaging in Non-Hodgkin's Lymphoma, Prostate Cancer, and Cutaneous T-Cell Lymphoma.
- What was a recent scientific validation for ST Innovative Diagnostics' technology?
- In May 2024, research on the presence and activity of Fibrinogen like protein 2 in platelets, which forms the basis of ST Innovative Diagnostics' technology, was published in journals.plos.org.